Stanford Tests Breakthrough Device for Age-Related Vision Loss

For millions of people living with vision loss from age-related macular degeneration (AMD), hope has often felt out of reach. The condition, which causes central vision to deteriorate over time, is the leading cause of blindness in older adults — and until now, it’s been considered incurable.

But a promising new study from Stanford Medicine may offer a glimpse of what the future could look like — literally. In a clinical trial of an experimental device called PRIMA, 27 out of 32 patients were able to regain the ability to read within just one year of treatment.

Left: Simulation of a patient’s vision with macular degeneration.Right: Simulation of the patient’s vision enhanced with the PRIMA eye prosthesis. Photo courtesy of Palanker Lab.

The PRIMA device is a type of retinal prosthetic, designed for people with advanced dry AMD. This condition destroys the macula, the part of the retina responsible for sharp central vision. Unlike glasses or contact lenses, which correct blurry vision, PRIMA aims to restore lost vision by bypassing damaged cells and sending signals directly to the brain.

The system involves two main components: a tiny wireless chip implanted beneath the retina, and a specialized pair of augmented-reality glasses. The chip receives images captured by the glasses and sends them to the brain through the remaining healthy cells in the eye. The system also allows users to zoom in, enhance contrast, and better recognize shapes and patterns — features that are especially useful for reading or navigating unfamiliar places.

“This is a first-of-its-kind approach to restoring functional vision in people who have lost it to macular degeneration,” said Dr. Daniel Palanker, professor of ophthalmology at Stanford and lead researcher on the study. “It doesn’t cure the disease, but it allows patients to regain abilities they thought were lost forever.”

The clinical trial results are remarkable. Before receiving the device, none of the 32 participants could read standard print. Within 12 months, over 80% of them could read letters and short words. Most reported improvements in daily life, such as recognizing faces, reading menus, or identifying street signs — tasks that had become impossible before.

Although the PRIMA system is still in the experimental stage and not yet widely available, these early results are encouraging. Researchers are continuing to monitor participants and adjust the technology, with hopes of expanding the trial and eventually seeking FDA approval.

Age-related macular degeneration affects nearly 20 million Americans, and its numbers are expected to rise as the population ages. While there are treatments to slow the wet form of AMD, options for dry AMD — the more common type — are extremely limited. That’s why news of potential vision restoration is generating excitement in the medical community.

Dr. Palanker emphasized that this breakthrough is not just about reading again. “It’s about giving people back their independence,” he said. “For someone who has lost their central vision, the ability to see even part of a face or a word can dramatically improve quality of life.”

While more testing is needed before the PRIMA device becomes widely accessible, the Stanford study marks a significant step forward in the fight against age-related blindness — and offers new hope to those who once thought their vision loss was permanent.